Download PDF
Synlett 2018; 29(13): 1776-1780
DOI: 10.1055/s-0037-1610183
letter
© Georg Thieme Verlag Stuttgart · New York

One-Pot Three-Component Synthesis of Bispyrazole-thiazole-pyran-2-one Heterocyclic Hybrids

Aicha Saidoun
a   Laboratoire de Chimie Organique Appliquée, Faculté de Chimie, Université des Sciences et de la Technologie Houari Boumediène, BP 32, El-Alia Bab-Ezzouar, 16111 Alger, Algeria   Email: yrachedi@gmail.com
,
Leila Boukenna
a   Laboratoire de Chimie Organique Appliquée, Faculté de Chimie, Université des Sciences et de la Technologie Houari Boumediène, BP 32, El-Alia Bab-Ezzouar, 16111 Alger, Algeria   Email: yrachedi@gmail.com
b   Centre de Recherche Scientifique et Technique en Analyses Physico-Chimiques (CRAPC), BP 384, Bou-Ismail, 42004 Tipaza, Algeria
,
Yahia Rachedi*
a   Laboratoire de Chimie Organique Appliquée, Faculté de Chimie, Université des Sciences et de la Technologie Houari Boumediène, BP 32, El-Alia Bab-Ezzouar, 16111 Alger, Algeria   Email: yrachedi@gmail.com
,
Oualid Talhi*
b   Centre de Recherche Scientifique et Technique en Analyses Physico-Chimiques (CRAPC), BP 384, Bou-Ismail, 42004 Tipaza, Algeria
c   QOPNA & Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal   Email: oualid.talhi@ua.pt   Email: artur.silva@ua.pt
,
Yacine Laichi
b   Centre de Recherche Scientifique et Technique en Analyses Physico-Chimiques (CRAPC), BP 384, Bou-Ismail, 42004 Tipaza, Algeria
,
Najet Lemouari
b   Centre de Recherche Scientifique et Technique en Analyses Physico-Chimiques (CRAPC), BP 384, Bou-Ismail, 42004 Tipaza, Algeria
,
Mohamed Trari
d   Laboratoire de Stockage et de Valorisation des Energies Renouvelables, Faculté de Chimie, Université des Sciences et de la Technologie Houari Boumediène BP 32, El-Alia Bab-Ezzouar, 16111 Alger, Algeria
,
Khaldoun Bachari
c   QOPNA & Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal   Email: oualid.talhi@ua.pt   Email: artur.silva@ua.pt
,
Artur M.S. Silva  *
c   QOPNA & Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal   Email: oualid.talhi@ua.pt   Email: artur.silva@ua.pt
› Author AffiliationsThanks are due to the University of Aveiro and FCT/MEC for financial support to the QOPNA research project (FCT UID/QUI/00062/2013), ­financed by national funds and, when appropriate, co-financed by FEDER under the PT2020 Partnership Agreement, as well as to the Portuguese NMR Network. We would also like to thank FCT/MEC and the General Directorate for Scientific Research and Technological ­Development – DGRSDT of Algeria and the Agence Thématique de ­Recherche en Sciences et Technologie ATRST for approving the co-­financed bilateral project PT-DZ/0005.
Further Information

Publication History

Received: 20 April 2018

Accepted after revision: 16 May 2018

Publication Date:
25 June 2018 (online)

    Permissions and Reprints All articles of this category


Abstract

A new series of some interesting bispyrazole-thiazole-pyran-2-one heterocyclic hybrids has been efficiently synthesized via a one-pot catalyst-free three-component reaction of α-bromoacetylated pyran-2-one derivatives, thiosemicarbazide, and polysubstituted-1-(1H-pyrazol-4-yl)butane-1,3-diones. This multicomponent procedure has been advantageously applied to prepare a structural diversity of hetero­cyclic hybrids characterized by extensive 1D and 2D NMR spectroscopic studies.

Key words

pyrazoles - thiazoles - pyran-2-ones - chromen-2-ones - three-component synthesis - 1D and 2D NMR

Supporting Information

    Supporting information for this article is available online at https://doi.org/10.1055/s-0037-1610183.
  • Supporting Information
 

  • References and Notes

    • 1a Spino C. Dodier MS. Sotheeswaran S. Bioorg. Med. Chem. Lett. 1998; 8: 3475
      Crossref
    • 1b Basile A. Sorbo S. Spadaro V. Molecules 2009; 14: 939
      CrossrefPubMed
    • 1c McGlacken GP. Fairlamb IJ. S. Nat. Prod. 2005; 22: 36
    • 1d Lee JS. Mar. Drugs 2015; 13: 1581
      CrossrefPubMed
    • 2a Egan D. O'Kennedy E. Moran E. Cox D. Prosser E. Thornes RD. Drug Metab. Rev. 1990; 22: 503
      Crossref
    • 2b Hatem AA. Tilal E. Abdullah A. Mohamed IA. Khalid AA. Abdul-Rahman MA. Eur. J. Med. Chem. 2013; 70: 358
      CrossrefPubMed
    • 2c Starks CM. Russell BW. Norman VL. Rice SM. O’Neil-Johnson M. Lawrence JA. Eldridge GR. Phytochemistry 2014; 98: 216
      CrossrefPubMed
    • 2d Behrami A. Dobroshi F. J. Chem. Pharm. Res. 2015; 7: 1087
    • 2e Ratnakar RK. Rao SP. Jitender DG. Poornachandra Y. Ganesh KC. Bioorg. Med. Chem. Lett. 2014; 24: 1661
      Crossref
    • 2f Jun M. Bacay AF. Moyer J. Webb A. Carrico-Moniz D. Bioorg. Med. Chem. Lett. 2014; 24: 4654
      Crossref
    • 2g Talhi O. Schnekenburger M. Panning J. Pinto DG. C. Fernandes JA. Paz FA. A. Jacob C. Diederich M. Silva AM. S. Bioorg. Med. Chem. 2014; 22: 3008
      CrossrefPubMed
    • 2h Veselinović JB. Matejić JS. Veselinović AM. D. Sokolović D. Biol. Nyssana 2016; 7: 167
    • 3a Fahr E. Pharm. Ztg. 1982; 127: 163
    • 3b Altomare C. Perrone G. Zonno MC. Evidente A. Pengue R. Fanti F. Polonelli L. J. Nat. Prod. 2000; 63: 1131
      CrossrefPubMed
    • 3c Altomare C. Pengue R. Favilla M. Evidente A. Visconti A. J. Agric. Food Chem. 2004; 52: 2997
      CrossrefPubMed
    • 3d McGlacken GP. Fairlamb I. J. Nat. Prod. Rep. 2005; 22: 369
      CrossrefPubMed
    • 3e Aiqun L. Xiaoming L. Yuchun F. Tianjiao Z. Qianqun G. Weiming Z. J. Antibiot. 2008; 61: 245
      CrossrefPubMed
    • 4a Lee S. Park SB. Org. Lett. 2009; 11: 5214
      CrossrefPubMed
    • 4b Orrego-Hernández J. Cobo J. Portilla J. Eur. J. Org. Chem. 2015; 5064
    • 5a Nasr MN. A. Said SA. Arch. Pharm. 2003; 336: 551
      CrossrefPubMed
    • 5b Ahasan NB. Rabiul MI. Bangladesh J. Pharm. 2007; 2: 81
    • 5c Shankaraiah N. Devaiah V. Reddy KL. Juvekar A. Sen S. Kurian N. Zingde S. Bioorg. Med. Chem. Lett. 2008; 18: 14681
    • 5d Nadia RM. Nahed YK. Amin FF. Ahmed AE. Der Pharma Chemica 2010; 2: 400
    • 5e Santhosh RM. Sravanthi S. Manjula A. Vittal RaoB. Madhava RB. Sridhar B. Bioorg. Med. Chem. Lett. 2012; 22: 5272
      Crossref
    • 6a Gupta P. Gupta JK. Halve AK. Int. J. Pharm. Sci. Res. 2015; 6: 2291
    • 6b Yu-Ying H. Kimiyoshi K. Hiroyuki T. Masayuki K. Fung FW. Tetrahedron Lett. 2011; 52: 3786
      Crossref
    • 6c Jania DH. Patela HS. Kehariab H. Modic CK. Appl. Organomet. Chem. 2010; 24: 99
    • 7a Sugiura S. Ohno S. Ohtani O. Izumi K. Kitamikado T. Asai H. Kato K. J. Med. Chem. 1977; 20: 80
      CrossrefPubMed
    • 7b Sakya SM. Rast B. Tetrahedron Lett. 2003; 44: 7629
      Crossref
    • 8a Siddiqui N. Arhad MF. Waquar A. Shamsher AM. Int. J. Pharm. Sci. Drug. Res. 2009; 1: 136
    • 8b Patt WC. Hamilton HW. Taylor MD. Ryan MJ. Taylor DG. J. Connolly CJ. C. Doherty AM. Klutchko SR. Sircar I. Steinbaugh BA. Batley BL. Painchaud CA. Rapundalo ST. Michniewicz BM. Olson SC. J. J. Med. Chem. 1992; 35: 2562
      CrossrefPubMed
    • 8c Barreca ML. Balzarini J. Chimirri A. De Clercq D. De Luca L. Holtje HD. Holtje M. Monforte AM. Monforte P. Pannecouque C. Rao A. Zappala MJ. J. Med. Chem. 2002; 45: 5410
      CrossrefPubMed
    • 8d Dinkar M. Chandewar AV. Mahendra RS. Der Chem. Sinica 2011; 2: 137
    • 8e Nepali K. Sharma S. Sharma M. Bedi PM.S. Dhar KL. Eur. J. Med. Chem. 2014; 77: 422
      CrossrefPubMed
    • 9a Ben Mohamed S. Rachedi Y. Hamdi M. Le Bideau F. Dejean C. Dumas F. Eur. J. Org. Chem. 2016; 2628
    • 9b Bouherou H. Saidoun A. Abderrahmani A. Abdellaziz L. Rachedi Y. Dumas F. Demenceau A. Molecules 2017; 2: 57
    • 10a Rachedi Y. Hamdi M. Speziale V. Synth. Commun. 1989; 19: 3427
    • 10b Aït-baziz N. Rachedi Y. Chemat F. Hamdi M. Asian J. Chem. 2008; 4: 2610
  • 11 Aït-Baziz N. Rachedi Y. Silva AM. S. Arkivoc 2010; (10) : 86
  • 12 Rachedi Y. Hamdi M. Sakellariou R. Spesiale V. Synth. Commun. 1991; 21: 1189
    Crossref
    • 13a Gelin S. Chantegrel B. Nadi A. J. Org. Chem. 1983; 48: 4078
      Crossref
    • 13b Bendaas A. Hamdi M. Sellier N. J. Heterocycl. Chem. 1999; 36: 1291
      Crossref
    • 14a Siddiqui N. Arshad M. Khan S. Acta Pol. Pharm. Drug Res. 2009; 66: 1617
    • 14b Hikem-Oukacha D. Rachedi Y. Hamdi M. Silva AM. S. J. Heterocycl. Chem. 2011; 48: 31
      Crossref
  • 15 General Procedure for the Synthesis of Bispyrazole-thiazole-pyran-2-one Hybrids 13a–d, 14, 15a-c, 15e and 16An equimolar mixture of the appropriate 3-(2-bromoacetyl)-pyran-2-one 10 or 12 (1 mmol), thiosemicarbazide 11 (91 mg, 1 mmol), and diketo-phenylpyrazoles (6a–e or 9, 1 mmol) was heated to reflux in absolute ethanol (10 mL) with vigorous stirring for 30–45 min. After completion of the reaction as indicated by TLC (using a 3:1 mixture of CHCl3/EtOH as eluent), the products were collected by filtration and then washed with hot ethanol to afford pure products.
  • 16 3-{2-[3′-(4-Chlorophenethyl)-5′-hydroxy-5-methyl-1′-phenyl-1′H,2H-(3,4′-bispyrazol)-2-yl]thiazol-4-yl}-4-hydroxy-6-methyl-2H-pyran-2-one (13b)C30H24ClN5O4S, white solid, 0.50 g (85%), mp 299–301 °C. 1H NMR (400 MHz, DMSO-d 6): δ = 2.21 (s, 3 H, 6-CH 3), 2.32 (s, 3 H, 5b-CH3), 2.76 (br s, 4 H, H-1c and H-2c), 5.97 (s, 1 H, H-5), 6.40 (s, 1 H, H-4b), 7.00 (d, J = 8.2 Hz, 2 H, H-2′′′,6′′′), 7.08 (d, J = 8.2 Hz, 2 H, H-3′′′,5′′′), 7.28–7.31 (m, 1 H, H-4′′), 7.45–7.49 (m, 2 H, H-3′′,5′′), 7.64–7.66 (m, 2 H, H-2′′,6′′), 7.90 (s, 1 H, H-5a), 11.53 (s, 1 H, 5′-OH), 12.53 (s, 1 H, 4-OH) ppm. 13C NMR (100 MHz, DMSO-d 6): δ = 13.8 (5b-CH3), 19.8 (6-CH3), 28.4 (C-1c), 33.2 (C-2c), 91.5 (C-4′), 94.5 (C-3), 101.1 (C-5), 111.5 (C-5a), 113.6 (C-4b), 122.8 (C-2′′,6′′), 126.5 (C-4′′), 128.2 (C-3′′′,5′′′), 129.2 (C-3′′,5′′), 130.4 (C-2′′′,6′′′), 130.8 (C-4′′′), 135.3 (C-3b), 138.8 (C-1′′), 140.3 (C-1′′′), 144.4 (C-4a), 149.7 (C-3′), 152.4 (C-5b), 160.6 (C-2a), 161.8 (C-2), 162.9 (C-6), 165.1 (C-5′), 168.3 (C-4) ppm. HRMS-ESI+: m/z calcd for [C30H24ClN5O4S + H]+: 586.1310; found: 586.1313.
  • 17 4-Hydroxy-3-{2-[5′-hydroxy-3′,5-dimethyl-1′-phenyl-1′H,2H-(3,4′-bispyrazol)-2-yl]thiazol-4-yl}-6-methyl-2H-pyran-2-one (14)C23H19N5O4S, white solid, 0.44 g (95%), mp 235–237 °C. 1H NMR (400 MHz, DMSO-d 6): δ = 2.07 (s, 3 H, 3′-CH3), 2.20 (s, 3 H, 6-CH3), 2.32 (s, 3 H, 5b-CH3), 6.01 (s, 1 H, H-5), 6.49 (s, 1 H, H-4b), 7.26–7.30 (m, 1 H, H-4′′), 7.44–7.48 (m, 2 H, H-3′′,5′′), 7.66–7.68 (m, 2 H, H-2′′,6′′), 7.94 (s, 1 H, H-5a), 11.55 (s, 1 H, 5-OH), 12.74 (s, 1 H, 4-OH) ppm. 13C NMR (100 MHz, DMSO-d 6): δ = 13.8 (5b-CH3and 3′-CH3), 19.8 (6-CH3), 91.8 (C-4′), 94.6 (C-3), 101.1 (C-5), 111.8 (C-5a), 113.2 (C-4b), 122.5 (C-2′′,6′′), 126.2 (C-4′′), 129.2 (C-3′′,5′′), 135.7 (C-3b), 138.9 (C-1′′), 144.4 (C-4a), 147.1 (C-3′), 152.5 (C-5b), 160.7 (C-2a), 161.8 (C-2), 162.9 (C-6), 165.3 (C-5′), 168.5 (C-4) ppm. HRMS-ESI+: m/z calcd for [C23H19N5O4S + H]+: 462.1231; found: 462.1230.
  • 18 3-{2-[5′-Hydroxy-3′-(4-methoxyphenethyl)-5-methyl-1′-phenyl-1′H,2H-(3,4′-bispyrazol)-2-yl]thiazol-4-yl}-2H-chromen-2-one (15e)C34H27N5O4S, white solid, 0.36 g (60%), mp 265–267 °C. 1H NMR (400 MHz, DMSO-d 6): δ = 2.34 (s, 3 H, 5b-CH3), 2.71 (br s, 4 H, H-1c and H-2c), 3.51 (s, 3 H, 4′′′-OCH3), 6.42 (br s, 2 H, H-5 and H-4b), 6.56 (d, J = 8.5 Hz, 2 H, H-3′′′,5′′′), 6.91 (d, J = 8.4 Hz, H-2′′′,6′′′), 7.06–7.09 (m, 1 H, H-6), 7.28–7.32 (m, 1 H, H-4′′), 7.38–7.40 (m, 1 H, H-8), 7.45–7.49 (m, 2 H, H-3′′,5′′), 7.53–7.57 (m, 1 H, H-7), 7.86–7.88 (m, 2 H, H-2′′,6′′), 7.96 (s, 1 H, H-4), 8.09 (s, 1 H, H-5a), 11.68 (s, 1 H, 5′-OH) ppm. 13C NMR (100 MHz, DMSO-d 6): δ = 13.9 (5b-CH3), 29.7 (C-1c), 33.2 (C-2c), 55.1 (4′′′-OCH3), 92.2 (C-4′), 112.8 (C-4b), 113.8 (C-3′′′,5′′′), 116.4 (C-8), 116.8 (C-5a), 119.1 (C-4a), 120.7 (C-3), 121.2 (C-2′′,6′′), 124.9 (C-6), 125.8 (C-4′′), 128.5 (C-5), 129.5 (C-2′′′,6′′′), 129.6 (C-3′′,5′′), 132.3 (C-7), 133.5 (C-1′′′), 135.3 (C-3b), 139.3 (C-4), 139.4 (C-1′′), 144.8 (C-4a), 150.9 (C-3′), 151.7 (C-5b), 152.8 (C-8a), 157.7 (C-4′′′), 159.0 (C-2), 160.3 (C-2a), 161.7 (C-5′) ppm. HRMS-ESI+: m/z calcd for [C34H27N5O4S + H]+: 602.1857; found: 602.1858.
  • 19 3-{2-[5′-Hydroxy-3′,5-dimethyl-1′-phenyl-1′H,2H-(3,4′-bispyrazol)-2-yl]thiazol-4-yl}-2H-chromen-2-one (16)C26H19N5O3S, white solid, 0.35 g (72%), mp 248–250 °C. 1H NMR (400 MHz, DMSO-d 6): δ = 2.09 (s, 3 H, 3′-CH3), 2.34 (s, 3 H, 5b-CH3), 6.42 (br s, 1 H, H-5), 6.50 (s, 1 H, H-4b), 7.06–7.10 (m, 1 H, H-6), 7.32 (s, 1 H, H-4′′), 7.37–7.39 (m, 1 H, H-8), 7.47–751 (m, 2 H, H-3′′,5′′), 7.52–7.56 (m, 1 H, H-7), 7.89–7.91 (m, 2 H, H-2′′,6′′), 8.06 (s, 1 H, H-4), 8.11 (s, 1 H, H-5a), 11.72 (s, 1 H, 5′-OH) ppm. 13C NMR (100 MHz, DMSO-d 6): δ = 13.8 (5b-CH3and 3′-CH3), 91.9 (C-4′), 112.7 (C-4b), 116.4 (C-8), 116.9 (C-5a), 119.1 (C-4a), 120.8 (C-3), 121.1 (C-2′′,6′′), 124.9 (C-6), 125.9 (C-4′′), 128.4 (C-5), 129.7 (C-3′′,5′′), 132.4 (C-7), 135.4 (C-3b), 139.2 (C-4), 139.5 (C-1′′), 144.8 (C-4a), 149.3 (C-3′), 151.7 (C-5b), 152.8 (C-8a), 159.0 (C-2), 160.60 (C-2a), 162.0 (C-5′) ppm. HRMS-ESI+: m/z calcd for [C26H19N5O3S + H]+: 482.1281; found: 482.1274.